2nd Quarter - Report

FOUNDATION MEDICINE, INC. for FOUNDATION MEDICINE, INC.

Firm
Client
Income
—
Expenses
$80,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Import of biological specimens for testing in a clinical laboratory

LobbyistCovered position, as disclosed
JENNIFER ROMANS —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2369 (119th), H.R. 5377 (119th), H.R. 3561 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.